Compare NNNN & SGRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NNNN | SGRY |
|---|---|---|
| Founded | 2021 | 2004 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Hospital/Nursing Management |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | N/A | 2015 |
| Metric | NNNN | SGRY |
|---|---|---|
| Price | $21.75 | $11.72 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $22.25 |
| AVG Volume (30 Days) | 29.0K | ★ 1.9M |
| Earning Date | 04-28-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 54.14 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,145,438,000.00 |
| Revenue This Year | N/A | $5.09 |
| Revenue Next Year | N/A | $5.67 |
| P/E Ratio | $446.57 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.91 | $11.61 |
| 52 Week High | $55.65 | $24.60 |
| Indicator | NNNN | SGRY |
|---|---|---|
| Relative Strength Index (RSI) | 45.15 | 29.27 |
| Support Level | $19.53 | N/A |
| Resistance Level | $30.70 | $16.15 |
| Average True Range (ATR) | 1.81 | 0.70 |
| MACD | 0.05 | -0.18 |
| Stochastic Oscillator | 37.28 | 4.11 |
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.
Surgery Partners Inc is a healthcare services company with an integrated outpatient delivery model focused on providing quality, cost-effective solutions for surgical and related ancillary care in support of both patients and physicians. It has one reportable segment: Surgical Facilities, which includes the operation of ASCs, surgical hospitals, anesthesia services, and multi-specialty physician practices, which earn revenues from contracts with patients in which the performance obligations are to provide health care services.